Depolama semptomu baskın alt üriner sistem semptomu olan hastalarda günlük tadalafil ve solifenasin kombinasyonunun etkinliği

Abstract

Amaç: Depo semptomları baskın olan benign prostat hiperplazi hastalarında tadalafil 5mg+solifenasin 5mg kombinasyonunun alt üriner sistem semptomları (AÜSS) ve erektil fonksiyonlar açısından etkinliğini değerlendirmek. Gereç ve Yöntemler: Ocak 2019 ile Aralık 2021 tarihleri ​​arasında AÜSS ile başvuran ve depolama semptomları baskın olan 40 yaş üstü erkek hastalar çalışmaya dahil edildi. Hastalara günlük tadalafil 5mg ve solifenasin 5mg tedavisi başlandı. AÜSS için aşırı aktif mesane semptom skoru (OABSS), uluslararası prostat semptom skoru (IPSS) ve erektil fonksiyon için uluslararası erektil fonksiyon indeksi-erektil fonksiyon (IIEF-EF) anketleri kullanıldı. Üç günlük mesane günlüğü ile günlük idrar sıklığı, noktüri, sıkışma ve idrar kaçırma sıklığı analiz edildi. On iki hafta sonra hastaların IPSS, OABSS ve IIEF-EF skorları değerlendirildi. Bulgular: Hastaların 12 haftalık tedavi öncesi ve sonrası semptom skorları ve mesane günlükleri karşılaştırıldığında, IPSS skorlarında (hem işeme, hem depolama, hem de toplam) anlamlı azalma (her biri için p<0,001), IIEF-EF skorlarında anlamlı artış ( p<0.001) ve Qmax değer yükselmesinde anlamlı artış gözlendi. Mesane günlükleri karşılaştırıldığında, tadalafil+solifenasin tedavisi sonrası 12. ayda gündüz işeme sayısı, noktüri sayısı ve sıkışma sayısı azaldı (p<0,001). Sonuç: Günde 5 mg tadalafil ve 5 mg solifenasin kombinasyonu, depolama semptomları baskın AÜSS/ED olan erkek hastalar için etkili ve güvenli bir tedavidir.

Keywords

• benign prostat hiperplazisi
• depolama
• tadalafil
• solifenasin
• erektil fonksiyon

Efficacy of combination of daily tadalafil and solifenacin in patients with storage symptom predominant lower urinary tract symptoms

Abstract

Objective: To evaluate the efficacy of tadalafil 5mg+solifenacin 5mg combination in terms of lower urinary tract symptoms (LUTS) and erectile functions in benign prostate hyperplasia patients with predominant storage symptoms. Material and Methods: Male patients over the age of 40 who presented with LUTS with predominant storage symptoms between January 2019 and December 2021 were included into the study. Daily tadalafil 5mg and solifenacin 5mg treatment were started to the patients. Overactive bladder symptom score (OABSS), international prostate symptom score (IPSS) for LUTS, and international erectile function index-erectile function (IIEF-EF) questionnaires were used for erectile function. Frequency of daily urinary frequency, frequency of nocturia, urgency and urinary incontinence were analyzed with a three-day bladder diary. Twelve weeks later, IPSS, OABSS and IIEF-EF scores of the patients were evaluated. Results: When the symptom scores and bladder diaries of the patients before and after 12 weeks of treatment were compared, significant decrease in IPSS scores (both voiding, storage and total) (p<0.001 for each), significant increase in IIEF-EF scores (p<0.001), and significant increase in Qmax value elevation was observed. When the bladder diaries were compared, the number of daytime micturitions, the number of nocturia and the number of urgency decreased in the 12th month after tadalafil+solifenacin treatment (p<0.001). Conclusion: The combination of tadalafil 5mg and solifenacin 5mg daily is an effective and safe treatment for male patients with storage symptoms predominant LUTS/ED.

Keywords

• benign prostate hyperplasia
• storage
• tadalafil
• solifenacin
• erectile function

References

1. [1] Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019; 65(5): 458-64. https://doi.org/10.1159/000496289
2. [2] Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016; 43(3): 289-97. https://doi.org/10.1016/j.ucl.2016.04.001
3. [3] De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017; 3(4-5): 352-63. https://doi.org/10.1016/j.euf.2017.11.004
4. [4] Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011; 60(4): 809-25. https://doi.org/10.1016/j.eururo.2011.06.037
5. [5] Cindolo L, Pirozzi L, Sountoulides P, et al. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015; 15: 96. https://doi.org/10.1186/s12894-015-0090-x
6. [6] Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia. Am J Mens Health. 2016; 10(2): 157-63. https://doi.org/10.1177/1557988315595692
7. [7] Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin. Aging Male. 2015; 18(1): 44-8. https://doi.org/10.3109/13685538.2014.951922
8. [8] Nomiya M, Burmeister DM, Sawada N, et al. Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol. 2013; 189(2): 754-61. https://doi.org/10.1016/j.juro.2012.07.141

9. [9] Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesical acrolein treatment. Eur Urol. 2011; 59(2): 264-71. https://doi.org/10.1016/j.eururo.2010.10.035
10. [10] Morelli A, Comeglio P, Filippi S, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2013; 73(4): 428-41. https://doi.org/10.1002/pros.22584
11. [11] Doroshyenko O, Fuhr U. Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009; 48(5): 281-302. https://doi.org/10.2165/00003088-200948050-00001
12. [12] Urakami S, Ogawa K, Oka S, et al. Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α(1) -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin. Low Urin Tract Symptoms. 2019; 11(3): 109-14. https://doi.org/10.1111/luts.12242
13. [13] Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148(5): 1549-57; discussion 64. https://doi.org/10.1016/s0022-5347(17)36966-5
14. [14] Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6): 822-30. https://doi.org/10.1016/s0090-4295(97)00238-0
15. [15] Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011; 60(5): 1010-6. https://doi.org/10.1016/j.eururo.2011.07.053
16. [16] Turunc T, Deveci S, Güvel S, Peşkircioğlu L. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Turk Uroloji Dergisi. 2007; 33: 45-9.
17. [17] Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006; 68(2): 318-23. https://doi.org/10.1016/j.urology.2006.02.042
18. [18] Culha MG, Degirmentepe RB, Ozbir S, Cakir SS, Homma Y. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. Int Urogynecol J. 2019; 30(12): 2121-6. https://doi.org/10.1007/s00192-019-04054-0
19. [19] Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology. 2011; 78(1): 126-33. https://doi.org/10.1016/j.urology.2011.02.055
20. [20] Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012; 61(5): 917-25. https://doi.org/10.1016/j.eururo.2012.01.013
21. [21] Burnett AL, Maguire MP, Chamness SL, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology. 1995; 45(3): 435-9. https://doi.org/10.1016/S0090-4295(99)80012-0
22. [22] Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J Urol. 2007; 177(2): 771-5. https://doi.org/10.1016/j.juro.2006.09.076
23. [23] Gong M, Dong W, Huang G, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015; 31(9): 1781-92. https://doi.org/10.1185/03007995.2015.1074067
24. [24] Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Morgan RJ, Mikhailidis DP. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol. 2003; 1(1): 27-31. https://doi.org/10.2174/1570161033386600
25. [25] Chang S, Hypolite JA, Zderic SA, Wein AJ, Chacko S, Disanto ME. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol. 2005; 289(4): R1124-30. https://doi.org/10.1152/ajpregu.00717.2003
26. [26] Schiff JD, Mulhall JP. The link between LUTS and ED: clinical and basic science evidence. J Androl. 2004; 25(4): 470-8. https://doi.org/10.1002/j.1939-4640.2004.tb02818.x
27. [27] Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008; 180(4): 1228-34. https://doi.org/10.1016/j.juro.2008.06.079
28. [28] Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int. 2016; 118(1): 153-60. https://doi.org/10.1111/bju.13406
29. [29] Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009; 6(2): 544-52. https://doi.org/10.1111/j.1743-6109.2008.01109.x
30. [30] Nieminen T, Tammela TL, Kööbi T, Kähönen M. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol. 2006; 176(6 Pt 1): 2551-6. https://doi.org/10.1016/j.juro.2006.07.154